Novel internal radiotherapy for refractory malignant brain tumors

2019 Fiscal Year Final Research Report

• Project/Area Number: 18K16592
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56010:Neurosurgery-related
• Research Institution: Yokohama City University
• Principal Investigator: Ohtake Makoto 横浜市立大学, 医学研究科, 客員研究員 (70644607)
• Project Period (FY): 2018-04-01 – 2020-03-31
• Keywords: malignant glioma / internal radiotherapy / Cu-ATSM / Brain tumor stem cells

Outline of Final Research Achievements

Glioblastoma is one of the most lethal brain tumor. Although standard therapy, including surgery plus alkylating chemotherapy with radiothearpy, outcome remains unsatisfactory, thus novel therapeutic approach is crucial. Herein, we established novel internal radiotherapy for malignant gliomas, using 64Cu-ATSM. We confirmed survival benefit in Cu-ATSM treated patient derived brain tumor xenograft model.

Free Research Field

脳神経外科

Academic Significance and Societal Importance of the Research Achievements

悪性脳腫瘍において組織内低酸素状態は放射線治療や化学療法の耐性につながる問題を有する。これに対して
我々はこれまでに脳腫瘍の低酸素領域をCu-ATSM PETを用いて非侵襲的に同定することに成功してきた。今回の研究ではCu-ATSMを用いた内部放射線治療効果の意義を動物レベルで見出した。将来的にはCu-ATSMを用いて悪性脳腫瘍の治療抵抗領域を標的とした内部照射を行うという独創的な治療法を提唱することを目指す。